Objectives: * To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV). * To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs)
Timeframe: Adverse event data was collected from vaccinated participants through Day 90.
Number of Vaccinated Participants With Related Adverse Events
Timeframe: Adverse event data was collected from vaccinated participants through Day 90.
Number of Vaccinated Participants With Serious Adverse Events (SAEs)
Timeframe: Adverse event data was collected from vaccinated participants through Day 90.